NCT00868361

A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel

A Phase 1 Open-label Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-Talampanel Following Oral Administration to Healthy Male

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to characterize the chemical breakdown and excretion of talampanel and its break down products in plasma, feces, and urine of healthy human volunteers.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Talampanel (non-radiolabeled), [14C] Talampanel	50 mg capsule single dose

Timeline

• Start date: 2009-05-01
• Primary completion: 2009-09-01
• Completion: 2009-09-01
• First posted: 2009-03-25
• Last updated: 2009-09-16

Locations

1 site across 1 country: United States